Singular Genomics Systems Stock Today
| OMIC Stock | USD 21.90 0.09 0.41% |
Performance13 of 100
| Odds Of DistressOver 68
|
Singular Genomics is trading at 21.90 as of the 30th of November 2024, a 0.41 percent increase since the beginning of the trading day. The stock's open price was 21.81. Singular Genomics has more than 68 % chance of experiencing financial distress in the next few years of operation. However, it had a very good returns during the last 90 days. Equity ratings for Singular Genomics Systems are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of September 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 27th of May 2021 | Category Healthcare | Classification Health Care |
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California. The company has 2.51 M outstanding shares of which 71.22 K shares are now shorted by private and institutional investors with about 2.3 trading days to cover. More on Singular Genomics Systems
Moving together with Singular Stock
Moving against Singular Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Singular Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Office Supplies, Measuring and Control Equipment, Health Care, Health Care Equipment & Supplies, Medical Instruments & Supplies, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSingular Genomics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Singular Genomics' financial leverage. It provides some insight into what part of Singular Genomics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Singular Genomics Systems (OMIC) is traded on NASDAQ Exchange in USA. It is located in 3010 Science Park Road, San Diego, CA, United States, 92121 and employs 255 people. Singular Genomics is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 54.77 M. Singular Genomics Systems conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 2.51 M outstanding shares of which 71.22 K shares are now shorted by private and institutional investors with about 2.3 trading days to cover.
Singular Genomics Systems currently holds about 287.98 M in cash with (73.65 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.05.
Check Singular Genomics Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Singular Genomics is $54.77 Million. Over half of Singular Genomics' outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Singular Ownership Details
Singular Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Hightower Advisors, Llc | 2024-06-30 | 17.6 K | |
| Tikvah Management Llc | 2024-06-30 | 10.6 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 726 | |
| Tower Research Capital Llc | 2024-06-30 | 528 | |
| Barclays Plc | 2024-06-30 | 409 | |
| Bank Of America Corp | 2024-06-30 | 367 | |
| Royal Bank Of Canada | 2024-06-30 | 87.0 | |
| Rhumbline Advisers | 2024-06-30 | 55.0 | |
| Bnp Paribas Arbitrage, Sa | 2024-06-30 | 36.0 | |
| Tang Capital Management Llc | 2024-09-30 | 372 K | |
| Deerfield Management Co | 2024-09-30 | 166.2 K |
Singular Genomics Historical Income Statement
Singular Stock Against Markets
Singular Genomics Corporate Management
| Eric Stier | General VP | Profile | |
| Daralyn Durie | G Counsel | Profile | |
| Samuel Ropp | Chief Officer | Profile | |
| Andrew Spaventa | CEO, Founder | Profile | |
| Eli Glezer | Chief Founder | Profile | |
| Dalen Meeter | Chief Officer | Profile | |
| Jeff Bullard | Head Sales | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Singular Genomics Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Singular Genomics. If investors know Singular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Singular Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (34.68) | Revenue Per Share 1.107 | Quarterly Revenue Growth 0.459 | Return On Assets (0.24) | Return On Equity (0.52) |
The market value of Singular Genomics Systems is measured differently than its book value, which is the value of Singular that is recorded on the company's balance sheet. Investors also form their own opinion of Singular Genomics' value that differs from its market value or its book value, called intrinsic value, which is Singular Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Singular Genomics' market value can be influenced by many factors that don't directly affect Singular Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Singular Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Singular Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Singular Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.